EL7.AI
StocksMedium•6 November 2026•
4 min read

Tandem Reaffirms Sales Guidance of $1.065–$1.085 Billion and Announces Executive Transition

Key Facts

1Tandem reaffirmed 2026 sales guidance at $1.065–$1.085 billion.
2Global sales were $283.7 million in the third quarter, up 14% from $249.3 million a year earlier.
3Gross margin rose to 57% from 54%, and gross profit increased to $160.4 million from $134.3 million.
4Jenette Banks will become president and CEO on November 16, 2026, and John Sheridan will leave his executive role at year-end.

Tandem Diabetes Care on November 5 reaffirmed its sales guidance for the year ending December 31, 2026, at a range of $1.065 billion to $1.085 billion, alongside its third-quarter results and a planned change in executive leadership. The company said estimated sales fall within the range, without announcing an adjustment. Global sales were $283.7 million in the third quarter, up 14% from $249.3 million in the same period of 2025. The company also announced that Jenette Banks will become president and chief executive officer and join the board of directors effective November 16, 2026. John Sheridan will leave the CEO post at year-end, after holding it since 2019, and will serve as an adviser to support the transition.

Sales growth was split between the U.S. and international markets, with the increase accelerating outside the United States. U.S. sales rose 9% to $191.0 million in the third quarter of 2026. International sales, meanwhile, increased 26% to $92.6 million, with growth at 27% on a constant-currency basis. These figures are year-over-year comparisons for the same period, while the company reported prior-year sales of $249.3 million for global sales overall. The comparison shows international markets grew faster than the U.S. market during the quarter, while U.S. sales remained higher than international sales in value.

Revenue growth was accompanied by an increase in gross profit and margin. Gross profit rose to $160.4 million in the third quarter of 2026, compared with $134.3 million in the corresponding quarter of 2025. Gross margin climbed to 57% from 54% a year earlier. The figures presented here did not provide a detailed explanation of the sources of margin improvement, but they place earnings performance alongside annual sales growth. Commenting on the results, Sheridan said the company was "expanding access to its life-changing technology, strengthening its business model, advancing its product pipeline and driving operational efficiency." The CEO linked the results to these operational priorities without announcing a change to annual sales guidance.

The company said it shipped approximately 33,000 pumps worldwide in the third quarter, including about 23,000 in the United States. The pharmacy channel also accounted for 15% of U.S. sales during the period, under a reimbursement model based on payment as used. Tandem said pharmacy benefit coverage for the channel had risen to about 50% of the U.S. population. This was accompanied by broader availability of its products outside the United States: the Tandem Mobi device became available in 12 countries, and compatibility of the t:slim X2 with the Abbott FreeStyle Libre 3 Plus sensor expanded to 11 international markets. The company presents these figures as developments in sales channels and geographic availability during the third quarter and through November 2026.

The leadership handover coincides with Banks’s appointment. The company said she has more than 30 years of global operating experience. Banks most recently served as president and CEO of GE HealthCare’s Patient Care Solutions unit, a business valued at $3.1 billion. Sheridan joined Tandem in 2013 as chief operating officer before becoming president and CEO in 2019. Banks’s appointment takes effect November 16, 2026, while Sheridan will remain through year-end and then serve as an adviser to support the planned leadership transition. The company did not attribute any investor-visibility or long-term financial outlook objective to the change.

On guidance, the company kept its 2026 sales range at $1.065 billion to $1.085 billion and said its sales estimate falls within that range. The information it announced included guidance for Adjusted EBITDA, a non-GAAP measure. The company did not provide a corresponding net income forecast, citing the difficulty of estimating future reconciliation items needed to compare the two measures. This disclosure came alongside the quarterly results, and the November 5 announcement did not indicate that annual guidance had been raised or lowered. The annual sales range for the period ending December 31, 2026, remains the guidance Tandem reaffirmed.

Upcoming events listed on the investor relations page include Tandem’s participation in the Jefferies Healthcare Conference on November 19, 2026, followed by the Piper Sandler Annual Healthcare Conference on December 3, 2026. The first event falls after Banks’s appointment is scheduled to take effect on November 16. The December conference comes before year-end, when the statement said Sheridan would retire from his executive role. The company did not provide new annual guidance figures or further details about the leadership transition in listing these events. The conferences remain the company’s next announced events in November and December.